DISCOVERY OF A LIVER TARGETED ORAL PD-L1 SMALL MOLECULE INHIBITOR FOR THE TREATMENT OF CHRONIC HEPATITIS B AND LIVER CANCER

被引：0

作者：

Roose, Heleen ^{[1
]}

Rekstyte-Matiene, Kristina ^{[1
]}

Stevens, Sarah K. ^{[2
]}

Gupta, Kusum ^{[2
]}

Chang, Sandra ^{[2
]}

Liu, Cheng ^{[2
]}

Serebryany, Vladimir ^{[2
]}

Adame, Lillian ^{[2
]}

Le, Kha ^{[2
]}

Stoycheva, Antitsa ^{[2
]}

Blatt, Lawrence M. ^{[2
]}

Beigelman, Leonid N. ^{[2
]}

Chanda, Sushmita ^{[2
]}

Smith, David B. ^{[2
]}

Symons, Julian ^{[2
]}

Jekle, Andreas ^{[2
]}

Wu, Tongfei ^{[1
]}

机构：

[1] Aligos Belgium BV, Leuven, Belgium

[2] Aligos Therapeut Inc, San Francisco, CA USA

来源：

HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1466-C

引用

页码：S566 / S567

页数：2

共 50 条

[21] In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
Lu, Chih-Hao
Chung, Wei-Min
Tsai, Chun-Hao
Cheng, Ju-Chien
Hsu, Kai-Cheng
Tzeng, Huey-En
SCIENTIFIC REPORTS, 2022, 12 (01)
[22] In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
Chih-Hao Lu
Wei-Min Chung
Chun-Hao Tsai
Ju-Chien Cheng
Kai-Cheng Hsu
Huey-En Tzeng
Scientific Reports, 12
[23] Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer
Islam, Mohammad Kaisarul
Stanslas, Johnson
PHARMACOLOGY & THERAPEUTICS, 2021, 227
[24] Preclinical activity of small-molecule oral PD-L1 checkpoint inhibitors capable of reinvigorating T cell responses from chronic hepatitis B patients
Thi, Emily P.
Cole, Andrew G.
Heffernan, Gavin
Iott, Christina
Ozturk, Seyma
Ganchua, Sharie C.
Nguyen, Dan
Graves, Ingrid
Ahuja, Vijay
Stever, Kim
Fan, Kristi
Quintero, Jorge G.
Kultgen, Steven G.
Shubina, Maria
Liu, Boya
Tang, Sunny
Harasym, Troy O.
Lam, Angela M.
Sofia, Michael J.
JOURNAL OF HEPATOLOGY, 2022, 77 : S848 - S848
[25] Discovery of Highly Potent Small-Molecule PD-1/PD-L1 Inhibitors with a Novel Scaffold for Cancer Immunotherapy
Xu, Yongling
Du, Huijie
Guo, Weibo
Liu, Beibei
Yan, Wenxin
Zhang, Chi
Qin, Long
Huang, Jingling
Wang, Hongxia
Wu, Shiqi
Ren, Weijie
Zou, Yi
Wang, Jie
Zhu, Qihua
Xu, Yungen
Gu, Hongfeng
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (05) : 4083 - 4099
[26] Discovery of a peptide inhibitor targeting human PD-L1 for cancer immunotherapy
Zou, S.
Jin, Y.
Liu, J.
Fan, S.
Feng, X.
Yang, Z.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 92 - 93
[27] Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
Singh, Vishakha
Khurana, Amit
Allawadhi, Prince
Banothu, Anil Kumar
Bharani, Kala Kumar
Weiskirchen, Ralf
FRONTIERS IN PHARMACOLOGY, 2021, 12
[28] Significance of soluble PD-L1 in patients with chronic hepatitis B and hepatitis C
柯若曼
China Medical Abstracts(Internal Medicine), 2023, 40 (02) : 84 - 84
[29] Small molecule PD-L1 inhibitor modulates expression of PD-L1 on the cell surface - a potential mechanism of blocking interaction with PD-1
Weitsman, G.
Chan, J. Nuo En
Nedbal, J.
Barber, P. R.
Volgina, A.
Stevens, C.
Poland, S.
Ameer-Beg, S.
Suhling, K.
Rios-Doria, J.
Ng, T.
EUROPEAN JOURNAL OF CANCER, 2022, 174 : S70 - S70
[30] CA-170-A Potent Small-Molecule PD-L1 Inhibitor or Not?
Musielak, Bogdan
Kocik, Justyna
Skalniak, Lukasz
Magiera-Mularz, Katarzyna
Sala, Dominik
Czub, Miroslawa
Stec, Malgorzata
Siedlar, Maciej
Holak, Tad A.
Plewka, Jacek
MOLECULES, 2019, 24 (15):

← 1 2 3 4 5 →